C4U

C4U Focuses on Developing Safe and Efficient Gene Therapies for Rare Diseases, Including Pediatric Conditions, Based on Its Proprietary Next-Generation CRISPR-Cas3 Gene Editing Platform. The CRISPR-Cas3 Technology Platform Is Similar to CRISPR-Cas9 in Terms of Engineering Design, Efficiency, and Delivery Methods, and Has Been Validated Through In Vitro and In Vivo Studies, Demonstrating the Following Significant Advantages: a. No Off-Target Effects (Enhanced Safety); b. High-Efficiency Knockout of Large Programmable Gene Sequences; c. A Fully Independent Patent Portfolio Exclusively Licensed Globally to C4U by Osaka University for Use in Eukaryotic Cells, Simplifying Re-Licensing Transactions and Providing a Stark Contrast to the Complex and Litigation-Heavy CRISPR-Cas9 Patent Landscape.